Lee's Summit Medical Center is proud to be part of the Sarah Cannon Cancer Institute HCA Midwest Health cancer network, providing local access to innovative clinical research trials, tumor profiling and genetic counseling; you can receive top cancer care in the comfort of your community hospital.

As part of the Sarah Cannon Cancer Institute at HCA Midwest Health, Lee's Summit Medical Center is a network-accredited cancer program. Accredited by the American College of Surgeons’ Commission on Cancer (CoC) quality program, the Sarah Cannon HCA Midwest Health cancer centers exceed the quality care standards set out by the CoC and consistently provide excellence in the delivery of comprehensive patient-centered care across our network of hospitals.

By addressing patient-centered needs and delivering quality care measured against national standards, patients and families have access to world-class, cutting-edge and innovative oncology services in their local communities. Patients receive the best cancer care close to home, while having access to the latest specialized technologies and clinical trial expertise available across the network.

Free Risk Assessments

Eating right and exercising are great steps toward leading a healthy life, but did you know your family history, age, and countless other factors can still put you at risk for health problems? Try our free risk assessments below to estimate your personal risk of developing breast, colon or rectal cancer, and identify your different types of risk factors.

Breast Cancer Risk Assessment

Colon Cancer Risk Assessment

For more information, contact us at (816) 282-5821 or visit hcamidwest.com. In addition to comprehensive prevention tools, diagnostics, cutting-edge therapies and surgical treatments, Sarah Cannon Cancer Institute HCA Midwest Health also offers a cancer wellness program to help support you every step of the way.

The Commission on Cancer (CoC) publishes the Cancer Programs Practice Profile Reports (CP³R) which includes two measures for colon cancer

The (CP³R) measurement helps facilities to:

  • Ensure patients are treated according to recognized standards of care,
  • Promote quality improvement activities, and
  • Accurately compare clinical performance among CoC accredited cancer programs.

The most current results (2013 cases) for the six breast cancer measures include:

Measure Type Quality Measure Us (2013) Missouri '12 National '12
Surveillance Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer. 100% 62% 63%
Quality Improvement Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection 100% 90% 88%
Surveillance Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes 100% 90% 85%
Accountability Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. 100% 93% 91%
Accountability Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ERA and PRA negative breast cancer 100% 95% 91%
Accountability Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ERA and/or PRA positive breast cancer 100% 92% 88%

Surveillance measures can be used at the community, regional, and/or national level to monitor patterns and trends of care in order to guide policymaking and resource allocation.

Quality Improvement measures are intended to be used for internal monitoring of performance within an organization or group so that analyses and subsequent remedial actions can be taken, as appropriate.

Accountability measures can be used for such purposes as public reporting, payment incentive programs, and the selection of providers by consumers, health plans, or purchasers.